# Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.

> **NCT05710783** · PHASE2,PHASE3 · COMPLETED · sponsor: **Laboratorio Avi-Mex, S.A. de C.V.** · enrollment: 4065 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** AVX-COVID/12
- **BIOLOGICAL:** ChAdOx-1-S[recombinant]

## Key facts

- **NCT ID:** NCT05710783
- **Lead sponsor:** Laboratorio Avi-Mex, S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-09
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-09-10
- **Target enrollment:** 4065 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710783, "Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05710783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*